Xenon Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Xenon Pharmaceuticals is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -2.73 Dollars per share in 2023, which was 16.38 lower than 2021. And about -0.15095 billion Dollars are reported as free cash flow in the financials of Xenon Pharmaceuticals 2023. No dividends were paid to the shareholders of the Xenon Pharmaceuticals stock NasdaqGM:XENE in the financial year 2023.

$9.43M

Revenue

$-2.06

Earnings Per Share

0.00%

Gross Margin %

$-,101.32M

Free Cash Flow

Revenue

9.43

Earnings Per Share

-2.06

Gross Margin %

0.00

Free Cash Flow

-,101.32

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017	2016	2015	2014
Rev.	Revenue	N/A	$9.43M	$18.44M	$32.17M	$6.83M	$0.00M	$0.31M	$1.80M	$15.58M	$28.37M
GM %	Gross Margin %	0.00%	0.00%	0.00%	-57.07%	0.00%	0.00%	0.00%	38.21%	82.27%	79.19%
OM	Operating Margin	0.00%	0.00%	0.00%	-97.31%	0.00%	0.00%	0.00%	0.00%	-60.10%	39.15%
EPS	Earnings Per Share	$-2.70	$-2.06	$-1.77	$-0.81	$-1.54	$-1.85	$-1.71	$-1.48	$-1.10	$3.28
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	63.04M	52.94M	36.83M	35.97M	26.77M	18M	17.93M	14.4M	14.22M
OCF	Operating Cash Flow	N/A	$-98.43M	$-69.50M	$-48.12M	$-4.63M	$0.00M	$0.00M	$-19.57M	$-18.10M	$0.27M
FCF	Free Cash Flow	N/A	$-,101.32M	$-71.55M	$-50.76M	$-5.87M	$0.00M	$0.00M	$-19.85M	$-18.65M	$-1.26M
FCFS	Free Cash Flow Per Share	$-2.31	$-1.62	$-1.36	$-1.41	$-0.23	$-1.81	$-1.61	$-1.28	$-1.31	$-0.40

Xenon Pharmaceuticals financials at a glance

Financials

Discover